Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy.

Literature DB >> 19012296

HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy.

Frank Alexis¹, Pamela Basto, Etgar Levy-Nissenbaum, Aleksandar F Radovic-Moreno, Liangfang Zhang, Eric Pridgen, Andrew Z Wang, Shawn L Marein, Katrina Westerhof, Linda K Molnar, Omid C Farokhzad.

Abstract

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2008 PMID： 19012296 PMCID： PMC3515656 DOI： 10.1002/cmdc.200800122

Source DB: PubMed Journal: ChemMedChem ISSN： 1860-7179 Impact factor: 3.466

× No keyword cloud information.

27 in total

1. Drug delivery. Drugs on target.

Authors: R Langer
Journal: Science Date: 2001-07-06 Impact factor: 47.728

2. Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators.

Authors: M Vittaz; D Bazile; G Spenlehauer; T Verrecchia; M Veillard; F Puisieux; D Labarre
Journal: Biomaterials Date: 1996-08 Impact factor: 12.479

3. Doxil in breast cancer.

Authors: F M Muggia
Journal: J Clin Oncol Date: 1998-02 Impact factor: 44.544

Review 4. RGD and other recognition sequences for integrins.

Authors: E Ruoslahti
Journal: Annu Rev Cell Dev Biol Date: 1996 Impact factor: 13.827

Review 5. Drug-monoclonal antibody conjugates for cancer therapy: potentials and limitations.

Authors: M V Pimm
Journal: Crit Rev Ther Drug Carrier Syst Date: 1988 Impact factor: 4.889

6. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2.

Authors: L A Maier; F J Xu; S Hester; C M Boyer; S McKenzie; A M Bruskin; Y Argon; R C Bast
Journal: Cancer Res Date: 1991-10-01 Impact factor: 12.701

7. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.

Authors: Omid C Farokhzad; Sangyong Jon; Ali Khademhosseini; Thanh-Nga T Tran; David A Lavan; Robert Langer
Journal: Cancer Res Date: 2004-11-01 Impact factor: 12.701

Review 8. Nanoparticles in cancer therapy and diagnosis.

Authors: Irène Brigger; Catherine Dubernet; Patrick Couvreur
Journal: Adv Drug Deliv Rev Date: 2002-09-13 Impact factor: 15.470

9. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers.

Authors: Frank Gu; Liangfang Zhang; Benjamin A Teply; Nina Mann; Andrew Wang; Aleksandar F Radovic-Moreno; Robert Langer; Omid C Farokhzad
Journal: Proc Natl Acad Sci U S A Date: 2008-02-13 Impact factor: 11.205

10. A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer.

Authors: K J O'Byrne; A L Thomas; R A Sharma; M DeCatris; F Shields; S Beare; W P Steward
Journal: Br J Cancer Date: 2002-07-01 Impact factor: 7.640

28 in total

Review 1. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.

Authors: Nazila Kamaly; Zeyu Xiao; Pedro M Valencia; Aleksandar F Radovic-Moreno; Omid C Farokhzad
Journal: Chem Soc Rev Date: 2012-03-05 Impact factor: 54.564

Review 2. Drug carrier interaction with blood: a critical aspect for high-efficient vascular-targeted drug delivery systems.

Authors: Daniel J Sobczynski; Margaret B Fish; Catherine A Fromen; Mariana Carasco-Teja; Rhima M Coleman; Omolola Eniola-Adefeso
Journal: Ther Deliv Date: 2015-08-14

HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy.

1. Drug delivery. Drugs on target.

2. Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators.

3. Doxil in breast cancer.

Review 4. RGD and other recognition sequences for integrins.

Review 5. Drug-monoclonal antibody conjugates for cancer therapy: potentials and limitations.

6. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2.

7. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.

Review 8. Nanoparticles in cancer therapy and diagnosis.

9. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers.

10. A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer.

Review 1. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.

Review 2. Drug carrier interaction with blood: a critical aspect for high-efficient vascular-targeted drug delivery systems.

Review 3. Nanocarriers for tracking and treating diseases.

Review 4. Bioavailability of phytochemicals and its enhancement by drug delivery systems.

Review 5. Nanodrug delivery systems: a promising technology for detection, diagnosis, and treatment of cancer.

Review 6. Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies.

Review 7. The role of HER2 in cancer therapy and targeted drug delivery.

8. Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles.

Review 9. Cellular uptake of nanoparticles: journey inside the cell.

10. Specific targeting of HER2-positive human breast carcinoma SK-BR-3 cells by amygdaline-Z_HER2 affibody conjugate.